Chadi hosts a duo of Canadiens to discuss quality of life and patient-reported outcomes in clinical trials: Christopher Booth, MD, and Michael Brundage, MSc, FRCPC, MD, both of Queen’s University. They begin by pontificating on whether quality of life is a “must” endpoint in designing interventional clinical trials today, the timeline of how “PROs” came to be a term and an important component of clinical trials, how PRO measures should differ across disease types and trials, and how PROs should be approached from an organizational and operational standpoint. Then, they discuss and use examples to illustrate how practical it is for providers to regularly measure quality of life and PROs, how payers should be approached for discussion on PRO measures, whether toxicity of therapies are underestimated by providers, and a whole lot more.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
